Published September 14, 2021
| Version v1
Patent
Open
BTK mutation and ibrutinib resistance
Contributors
Patent applicant:
Description
Provided herein are mutations in Bruton's Tyrosine Kinase (BTK) that confer resistance to treatment with a BTK inhibitors, such as Ibrutinib, and compositions and methods for the treatment, diagnosis, and characterization of BTK-inhibitor-resistant cancers.
Files
US11118233.pdf
Files
(1.8 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:1c361962361aa98c7a4d4669519d2dc0
|
1.8 MB | Preview Download |
Additional details
Identifiers
- Patent number
- US 11118233 B2
- Patent application number
- US 201716302015 A
- Other
- oai:uchicago.tind.io:7427
Dates
- Patent filed
-
2017-05-18